Malik, P. S. ; Jain, D. ; Kumar, L. (2016) Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer Oncology, 91 (s1). pp. 26-34. ISSN 0030-2414
Full text not available from this repository.
Official URL: https://www.karger.com/Article/FullText/447578
Related URL: http://dx.doi.org/10.1159/000447578
Abstract
The advent of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has led to a paradigm shift in the management of advanced adenocarcinoma of the lung. The key to success of these therapies lies in the precise identification of their molecular targets, i.e. sensitizing EGFR mutations. The variations in the prevalence of these mutations among different ethnicities necessitate regional studies for a better understanding of the molecular epidemiology of the disease and clinical decision-making. This is even more relevant for countries like India where genetic heterogeneity is a rule. Here, we make an attempt to review the epidemiology of EGFR mutations in India versus other Asian countries and the West. We also review the clinical experience with EGFR TKIs and suggest the way forward in a resource-limited setting.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to Karger Publisher. |
Keywords: | Epidermal Growth Factor Receptor Mutation; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors; Personalized Medicine; Pathological and Molecular Profile |
ID Code: | 111335 |
Deposited On: | 25 Sep 2017 12:44 |
Last Modified: | 25 Sep 2017 12:44 |
Repository Staff Only: item control page